MedTrace Logo

Novel Screening Strategies for Scleroderma PAH

NCT01959815 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 156

Last updated 2021-11-15

No results posted yet for this study

Summary

Patients with scleroderma can develop heart failure due to high blood pressure in the lungs (a condition called pulmonary arterial hypertension). It is important to find pulmonary arterial hypertension early, so that it can be treated before heart failure develops. However, the tests that we now use to find the earliest form of this disease in scleroderma patients are not good enough. This study will examine whether tests performed during exercise can improve our ability to find early pulmonary arterial hypertension. The study will also try to identify genes that are responsible for the development of pulmonary arterial hypertension.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Scott H Visovatti, MD · University of Michigan

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-26
Primary Completion
2019-11-06
Completion
2019-11-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01959815 on ClinicalTrials.gov